

S. No.	Particulars	Details	
1	The board of directors in its report shall disclose any material change in the scheme(s) and whether Scheme(s) is/are in compliance with the regulations	Refer the Board's Report of the Integrated Annual Report 2025-26.	
A.	Relevant disclosures has been made in terms of the 'Guidance note on accounting for employee share-based payments' issued by ICAI or any other relevant accounting standards as prescribed from time to time.	Please refer to Note No. 2.45 contained in the Notes to Accounts forming part of Annual Standalone Financial Statements for the Financial Year ended on March 31, 2026.	
B.	Diluted Earnings per Share (EPS) on issue of Shares on Exercise of Options calculated in accordance with Indian Accounting Standard (Ind AS) 33	Rs. 24.62/- (As per Note No.2.35 of Standalone Financials)	
C. Details related to Plan			
S. No.	Description	Rainbow Children's Medicare Limited – Employees Stock Unit Plan 2023 ("Stock Unit Plan 2023"/ "Plan")	Rainbow Children's Medicare Limited – Employees Stock Unit Plan 2025 ("Stock Unit Plan 2025"/ "Plan")
i.	Date of Shareholders' approval Total number of options approved under the Scheme and in force Vesting Requirements Exercise Price or Pricing Formula Maximum term of options granted Source of shares (primary, secondary or combination) Variation in terms of options	May 6, 2023 4,00,000 Units granted shall not vest earlier than the minimum vesting period of 1 year and not later than maximum vesting period of 5 years from the date of grant. Exercise price per unit shall be the face value of Shares of the Company as on Grant Date. 5 Years Primary No variation	April 2, 2025 10,15,000 Units granted shall not vest earlier than the minimum vesting period of 1 year and not later than maximum vesting period of 10 years from the date of grant. The exercise price per option shall be determined by the Nomination and Remuneration Committee subject to a maximum discount of up to 20% from the market price of shares as on the date of Grant. 10 Years Secondary No variation
ii	Method used to account for RSU / ESOP	Fair Value Method	Fair Value Method
iii	Where the company opts for expensing of the options using the intrinsic value of the options, the difference between the employee compensation cost so computed and the employee compensation cost that shall have been recognized if it had used the fair value of the options shall be disclosed. The impact of this difference on profits and on EPS of the company shall also be disclosed.	Not applicable	Not applicable
iv	Options movement during the year: Number of options outstanding at the beginning of the period Number of options granted during the year Number of options forfeited/ lapsed during the year Number of options vested during the year No. of options exercised during the year No. of shares arising as a result of exercise of options Money realized by exercise of options (INR) if scheme is implemented directly by the Company Loan repaid by the Trust during the year from exercise price received (in INR) No. of options outstanding at the end of the year No. of options exercisable at the end of the year	29,931 Nil Nil 7,483 7,483 7,483 - Not applicable - 22,448	2,46,470 2,46,470 32,980 Nil Nil Nil - Not applicable - 2,13,490
v	Weighted-average exercise prices and weighted-average fair values of options shall be disclosed separately for options whose exercise price either equals or exceeds or is less than the market price of the stock.	Please refer 2.45 contained in the Notes to Accounts forming part of Annual Standalone Financial Statements for the Financial Year ended on March 31, 2026.	
vi	Employee wise details (name of employee, designation, number of options granted during the year, exercise price) of options granted to :	During the year, no options were granted.	
	(a) Senior Management Personnel	A. Dr. Prashanth K, Group Medical Director, has been granted 26,150 Stock Units at an exercise price of ₹1246/- per unit. B. Mr. Srinath Metta, Chief Strategy and Growth Officer, has been granted 24,100 Stock Units at an exercise price of ₹1246/- per unit. C. Ms. Shreya Mitra, Company Secretary and Compliance Officer, has been granted 2,060 Stock Units at an exercise price at an exercise price of ₹1246/- per unit. D. Mr. Abrarali Dalal, Chief Executive Officer, has been granted 1,00,000 Stock Units at an exercise price at an exercise price of ₹1010/- per unit.	
	(b) Any other employees who received a grant in any one year of Options amounting to 5% or more of the Options granted during that year.	Yes: A. Dr. Prashanth K, Group Medical Director, has been granted 26,150 Stock Units. B. Mr. Srinath Metta, Chief Strategy and Growth Officer, has been granted 24,100 Stock Units. C. Mr. Abrarali Dalal, Chief Executive Officer, has been granted 1,00,000 Stock Units. D. Ananth Nanjunda Rao, Senior Vice President - Operations, has been granted 14,460 Stock Units*.	
	(c) Identified employees who were granted Options during any one year, equal to or exceeding 1% of the issued capital (excluding outstanding warrants and conversions) of the Company at the time of grant.	Not applicable	
vii	A description of the method and Significant assumption used during the year to estimate the fair value of options including the following information: (a) the weighted-average values of share price, exercise price, expected volatility, expected option life, expected dividends, the risk-free interest rate and any other inputs to the model; (b) the method used and the assumptions made to incorporate the effects of expected early exercise; (c) how expected volatility was determined, including an explanation of the extent to which expected volatility was based on historical volatility; and (d) whether and how any other features of the options granted were incorporated into the measurement of fair value, such as a market condition.	The fair value at grant date is determined using the Black Scholes valuation option-pricing model which takes into account the exercise price, the term of the option, the share price at grant date and expected price volatility of the underlying share, the expected dividend yield and the risk free interest rate for the term of the option.	The fair value at grant date is determined using the Black Scholes valuation option-pricing model which takes into account the exercise price, the term of the option, the share price at grant date and expected price volatility of the underlying share, the expected dividend yield and the risk free interest rate for the term of the option.
		Please refer 2.45 contained in the Notes to Accounts forming part of Annual Standalone Financial Statements for the Financial Year ended on March 31, 2026.	
viii	Disclosures in respect of transactions made by Trust under ESOP Scheme	Not applicable	
i	Name of the Trust	Rainbow Employees Welfare Trust	
ii	Details of the Trustee(s)/Settlor	Ms. Maddirala Pranathi Subrahmanyam (trustee), Mr. Meka Yugandhar (trustee) Mr. Vikas Maheshwari (Settlor)	
iii	Amount of loan disbursed by Company/any Company in the group, during the year	Nil	
iv	Amount of loan outstanding (repayable to Company/ any Company in the group) as at the end of the year	Nil	
v	Amount of loan, if any, taken from any other source for which Company/any Company in the group has provided any security or guarantee	Nil	
vi	Any other contribution made to the Trust during the year	Nil	
viii	Brief details of transactions in shares by the Trust	Not applicable	
i	Held at the beginning of the year	Nil	
ii	Acquired during the year	1,80,000	
iii	Sold during the year	Nil	
iv	Transferred to the employees during the year	Nil	
v	Held at the end of the year	1,80,000	

* 14,460 Stock Units granted to Mr. Ananth Nanjunda Rao, Senior Vice President – Operations, were cancelled during the year owing to his resignation.